Xiaoqing Liu

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i>-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Li Zhang, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2018 · 327 citations · Full text

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer

Guanshan Zhu, Xin Ye, Zhengwei Dong et al. · Journal of Molecular Diagnostics · 2015 · 197 citations · Full text

Polymerase Chain Reaction, Plasma Cell–free Dna, Oncology +10

Results of a global phase II study with crizotinib in advanced <i>ALK</i>-positive non-small cell lung cancer (NSCLC).

Dong‐Wan Kim, Myung‐Ju Ahn, Yuankai Shi et al. · Journal of Clinical Oncology · 2012 · 159 citations

Tumor Response, Medicine, Cancer Management +13

The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies

Xiaoqing Liu, Yachao Lu, Guanshan Zhu et al. · Journal of Clinical Pathology · 2013 · 148 citations · Full text